UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000022566
Receipt number R000026006
Scientific Title To calculate efficacy and safety of LDV/SOF to HCV genotype 2, Phase 3b randomised non-blinded multiceter trial.
Date of disclosure of the study information 2016/06/01
Last modified on 2016/06/23 13:46:40

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

To calculate efficacy and safety of LDV/SOF to HCV genotype 2, Phase 3b randomised non-blinded multiceter trial.

Acronym

The efficacy and safety of LDV/SOF to HCV genotype 2.
(GS-US-337-1903)

Scientific Title

To calculate efficacy and safety of LDV/SOF to HCV genotype 2, Phase 3b randomised non-blinded multiceter trial.

Scientific Title:Acronym

The efficacy and safety of LDV/SOF to HCV genotype 2.
(GS-US-337-1903)

Region

Japan


Condition

Condition

HCV genotype 2

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

The efficacy and safety of LDV/SOF to HCV genotype 2.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

SVR with 12 week after treatment

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

LDV/SOF treatment for 12 weeks
CH or LC

Interventions/Control_2

SOF/RBV treatment for 12 weeks
CH or LC

Interventions/Control_3

LDV/SOF treatment for 12 weeks
CH or LC
Not tolerant of RBV

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

CH or LC

Key exclusion criteria

HCC

Target sample size

4


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Michiharu Komatsu

Organization

Shinshu University of Medicine

Division name

Gastroenterology

Zip code


Address

Asahi 3-1-1, Matsumoto, Nagano

TEL

0263-37-2634

Email

komichi@shinshu-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Michiharu Komatsu

Organization

Shinshu University of Medicine

Division name

Gastroenterology

Zip code


Address

Asahi 3-1-1, Matsumoto, Nagano

TEL

0263-37-2634

Homepage URL


Email

komichi@shinshu-u.ac.jp


Sponsor or person

Institute

Shinshu University of Medicine

Institute

Department

Personal name



Funding Source

Organization

Gilead-Sciences Inc

Organization

Division

Category of Funding Organization

Outside Japan

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 06 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2016 Year 05 Month 11 Day

Date of IRB


Anticipated trial start date

2016 Year 06 Month 06 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This clinical trial is a part of GS-US-337-1903.We don't continue this clinical trial information in this web pages.This clinical trial results will be reported by Gilead Sciences,Inc.


Management information

Registered date

2016 Year 06 Month 01 Day

Last modified on

2016 Year 06 Month 23 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026006


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name